Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial.

Pharmacol Res Perspect · 2015 · PMC4317226 · PMID 25692013

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Recently, it has been reported that losmapimod reduced CRP and fibrinogen levels, but at 24 weeks the effects did not reach statistical significance (Watz et al. 2014 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.